Topiroxostat

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]

Topiroxostat
Clinical data
Trade namesTopiloric, Uriadec
ATC code
  • None
Legal status
Legal status
  • Approved in Japan
Identifiers
IUPAC name
  • 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H8N6
Molar mass248.249 g·mol−1
3D model (JSmol)
SMILES
  • C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
InChI
  • InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
  • Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]

Synthesis
Patent:[3]

4-Cyanopyridine [100-48-1] and 2-cyanoisonicotinic acid hydrazide [135048-32-7].

References
  1. "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. {{cite journal}}: Cite journal requires |journal= (help)
  2. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.
  3. EP1471065 idem Hiroshi Nakamura, et al. WO 2003064410 (Fuji Yakuhin Co Ltd).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.